RELA and ovarian carcinoma: Previous studies have shown that overexpression of mortalin is correlated to the malignancy of ovarian cancer, and that downregulation of mortalin can significantly enhance the sensitivity of cisplatin resistance in ovarian cancer cells and reduce their proliferation and invasion.42 Thus, the cisplatin‐resistant human ovarian cancer cell line A2780CP and the cisplatin‐sensitive human ovarian cancer cell line A2780S were selected to study the interaction between NF‐κB p65 and mortalin.